These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39082955)

  • 1. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
    Argüelles-Arias F; Rodriguez González FJ; González Antuña J; Castro Laria L; Gutiérrez Martinez F; Alcaín Martinez G; Maldonado Pérez B; Camargo Camero R; Martos Van Dussen JV; Fernández Castañer A; Valdés Delgado T
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 39082955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
    Argüelles-Arias F; Valdés Delgado T; Maldonado Pérez B; González Antuña J; Castro Laria L
    Therap Adv Gastroenterol; 2023; 16():17562848231191670. PubMed ID: 37655058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
    Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
    J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.
    Yao J; Peng X; Zhong Y; Su T; Bihi A; Zhao J; Liu T; Wang W; Hu P; Zhang M; Zhi M
    Front Med (Lausanne); 2023; 10():1105981. PubMed ID: 37554510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease.
    González-Antuña J; Valdés-Delgado T; Maldonado-Pérez B; Belvis-Jiménez M; Castro-Laria L; Merino-Bohórquez V; Calleja-Hernández MÁ; Castro-Martínez P; Charpentier C; Argüelles-Arias F
    Therap Adv Gastroenterol; 2024; 17():17562848241271980. PubMed ID: 39257470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
    Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
    Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
    Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
    Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
    Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
    Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
    Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
    Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
    Mínguez A; Coello E; Garrido A; Ripoll P; Gomez M; Aguas M; Iborra M; Cerrillo E; Tortosa L; Bayarri V; Bueno N; Fernández MJ; Marqués R; Nos P; Bastida G
    Gastroenterol Hepatol; 2024 Sep; ():502253. PubMed ID: 39270973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 15. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
    Sedano R; Guizzetti L; McDonald C; Jairath V
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1497-1498.e1. PubMed ID: 32763479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
    Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
    Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.
    Bertin L; Barberio B; Gubbiotti A; Bertani L; Costa F; Ceccarelli L; Visaggi P; Bodini G; Pasta A; Sablich R; Urbano MT; Ferronato A; Buda A; De Bona M; Del Corso G; Massano A; Angriman I; Scarpa M; Zingone F; Savarino EV
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.